Reta vs tirzepatide compared: FDA status, receptor targets, trial weight-loss results, side effects, and why no head-to-head study exists yet.
Reta and tirzepatide are two different drugs, not two names for the same medication. Tirzepatide is FDA-approved and sold as Mounjaro and Zepbound, while "reta" is short for retatrutide, an investigational triple-agonist that is not approved for human use in the United States. The biggest practical difference is availability: one can be prescribed today, and the other can only be obtained through a clinical trial.
What Is Reta (Retatrutide)?
Retatrutide is an investigational injectable that targets three hormone receptors at once: GLP-1, GIP, and glucagon. The added glucagon activity is what separates it from every weight-management drug currently on the market.
In a Phase 2 trial published in the New England Journal of Medicine in 2023, adults with obesity who took 12 mg weekly lost an average of about 24% of their body weight over 48 weeks. That figure is widely quoted online, but it comes from a single mid-stage study rather than a completed Phase 3 program.
- Status: Investigational; Phase 3 trials ongoing
- Route: Weekly subcutaneous injection
- Brand name: None — no approved product exists
What Is Tirzepatide?
Tirzepatide is a dual GLP-1 and GIP receptor agonist approved by the FDA. It is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in adults who meet specific criteria.
In the SURMOUNT-1 trial, adults without diabetes who received the highest dose lost an average of roughly 21% of their body weight over 72 weeks. Because tirzepatide is approved, it comes with a defined dose-escalation schedule, monitoring guidance, and a well-documented safety record.
Reta vs Tirzepatide: Side-by-Side Comparison
| Feature | Retatrutide (reta) | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1, GIP, and glucagon | GLP-1 and GIP |
| FDA approval | Not approved | Approved (Mounjaro, Zepbound) |
| How it is obtained | Clinical trials only | Prescription |
| Dosing | Weekly injection; trial doses up to 12 mg | Weekly injection; 2.5 mg to 15 mg |
| Average weight loss in trials | About 24% at 48 weeks (12 mg, Phase 2) | About 21% at 72 weeks (15 mg, Phase 3) |
| Common side effects | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting, constipation |
| Long-term safety data | Limited | Extensive |
Those percentages come from separate trials with different designs, doses, and durations, so they cannot be read as a direct head-to-head result.
Which One Produces More Weight Loss?
Reta has posted a higher average weight-loss number in its Phase 2 study, but that does not automatically make it the stronger option. Cross-trial comparisons are unreliable because the study populations, treatment lengths, and dosing schedules all differ.
The honest answer to retatrutide vs tirzepatide which is better is that nobody knows yet. No randomized trial has compared the two drugs directly, and retatrutide may never reach the market if later-stage results or safety reviews raise concerns.
Body composition is another open question. retatrutide muscle loss vs tirzepatide is a frequent topic in fitness communities, and while lean-mass loss is documented with rapid weight reduction in general, there is not enough data to say whether one drug spares muscle better than the other.
Safety and Approval Status
Tirzepatide carries boxed warnings for thyroid C-cell tumors and pancreatitis, and it is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2. Common side effects include nausea, vomiting, diarrhea, and constipation, usually worst during dose escalation.
Retatrutide shares the GLP-1 class side-effect profile, and its added glucagon activity may influence heart rate, liver enzymes, and blood sugar. Because it is still experimental, its long-term risk profile remains unknown.
Retatrutide is not FDA-approved for human use in the United States, and it cannot legally be prescribed outside of a clinical trial.
Anyone considering either drug should talk with a licensed healthcare professional, especially if they use insulin, have kidney or gallbladder disease, or are pregnant or breastfeeding.
How Reta and Tirzepatide Fit With Other Options
Reta and tirzepatide are not the only compounds people research. aod 9604 vs tirzepatide comes up often because AOD 9604 is marketed as a fat-loss peptide with a very different mechanism and a much thinner evidence base.
Another frequent comparison is cagrilintide vs tirzepatide, which pits an amylin analog against a dual GIP/GLP-1 agonist. Not every comparison involves an injectable either; lipo-c vs tirzepatide reflects interest in lipotropic injections, which are not FDA-approved for weight loss and have little supporting clinical evidence.
In practice, the only option in this group with regulatory approval and a defined dosing schedule is tirzepatide.
Bottom Line
Tirzepatide is the available, well-studied choice, and retatrutide is an experimental drug with promising early data. If you are weighing reta vs tirzepatide for real-world use, availability and long-term safety data should carry more weight than a single headline number.
Discuss any weight-management medication with a healthcare provider who can review your history, current medications, and risk factors before you start.
RELATED PEPTIDE TOPICReta peptideFrequently Asked Questions
Is reta the same thing as tirzepatide?
No. Reta is shorthand for retatrutide, an investigational triple agonist that targets GLP-1, GIP, and glucagon and is not FDA-approved. Tirzepatide is an approved dual GLP-1 and GIP agonist sold as Mounjaro and Zepbound.
Can you get retatrutide in the United States?
No. Retatrutide is not FDA-approved for human use, so it is only available through enrolled clinical trials. Products labeled as retatrutide from online peptide sellers are unregulated and have not been verified for purity, dose, or sterility.
Which causes more weight loss, reta or tirzepatide?
In separate trials, retatrutide produced about 24% average weight loss at 48 weeks and tirzepatide produced about 21% at 72 weeks. No head-to-head trial has compared them, so those numbers should not be treated as a direct ranking.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.